8-K: Cerus Corp Secures $248 Million BARDA Contract for Red Blood Cell Program, Faces Setback in Europe

Cerus Corporation announced a new $248 million contract with BARDA to advance its red blood cell program in the U.S., while its CE Mark review in Europe concluded without approval.

Summary

• Cerus Corporation has received a new contract from BARDA worth up to $248 million to support its INTERCEPT red blood cell program in the U.S.
• The funding will support activities including product design improvements, commercial manufacturing scale-up, and a planned FDA premarket approval application.
• The initial award from BARDA is $32.1 million, with additional funding contingent on meeting specific milestones.
• Cerus's CE Mark review in Europe for its red blood cell system concluded without approval due to insufficient data on the impurity profile of the final product.
• The company is now assessing strategies for a potential new regulatory submission in Europe, leveraging data from its U.S. Phase 3 trials.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with a significant positive development (BARDA contract) offset by a negative one (CE Mark rejection). The overall sentiment is cautiously optimistic due to the potential of the U.S. program, but tempered by the European setback and regulatory uncertainties.

Positives

• The new BARDA contract provides significant funding of up to $248 million for the U.S. red blood cell program.
• The funding will support product improvements, manufacturing scale-up, and the FDA approval process.
• Positive topline results from the ReCePI study, a pivotal U.S. Phase 3 clinical trial, support the efficacy of the INTERCEPT RBCs.
• The company is actively enrolling patients in the RedeS clinical trial, another pivotal U.S. Phase 3 trial.
• Cerus is exploring how data from the U.S. Phase 3 ReCePI trial can be used to support a broader clinical indication in a potential new CE Mark submission.

Negatives

• The CE Mark review in Europe concluded without approval, requiring a new regulatory submission.
• The European regulatory authority found the data on the impurity profile of the final product to be insufficient.
• The company is still assessing the potential impact of new study sites on the timing of the RedeS study completion and PMA submission.
• The new BARDA contract is subject to potential termination by BARDA and is dependent on continued funding from Congress.

Risks

• BARDA funding is subject to government actions and may be less than anticipated.
• The FDA could require additional clinical data, which would require additional funding.
• There is a risk that Cerus may not be able to meet FDA requirements for the PMA submission.
• The company may not be able to complete enrollment in the RedeS study or report data in a timely manner.
• Cerus may be unable to address the issues that prevented CE mark approval in Europe.
• There are risks associated with commercialization and market acceptance of the INTERCEPT RBC system.
• The company's future capital requirements and the sufficiency of its cash resources are uncertain.

Future Outlook

Cerus plans to submit a modular PMA application to the FDA for the INTERCEPT RBC system, contingent on the completion of the RedeS clinical trial. The company is also assessing strategies for a new regulatory submission in Europe, potentially leveraging data from its U.S. Phase 3 trials.

Management Comments

• Obi Greenman, Cerus president and chief executive officer, stated they are pleased with the progress of the U.S. RBC program and the additional support from BARDA.
• Richard Benjamin, M.D., Ph.D., Cerus chief medical officer, mentioned that ReCePI investigators will be presenting study data at the Annual AABB meeting.
• Carol Moore, Cerus senior vice president, stated they believe strongly in the need for pathogen inactivated RBCs and are assessing how to address the issues raised by the European regulatory authority.

Industry Context

This announcement highlights the ongoing efforts to improve blood safety through pathogen reduction technologies. The new BARDA contract underscores the U.S. government's commitment to advancing such technologies. The setback in Europe demonstrates the challenges in navigating different regulatory pathways.

Comparison to Industry Standards

• Cerus's INTERCEPT system is a leading technology in pathogen reduction for blood products, with existing approvals for platelets and plasma.
• The $248 million BARDA contract is a significant investment in the development of red blood cell pathogen reduction, reflecting the importance of this area.
• The European regulatory hurdle highlights the stringent requirements for medical device approvals in the EU, which can be more challenging than in the US.
• Other companies in the blood safety space include Haemonetics and Terumo BCT, which also offer technologies for blood processing and pathogen reduction, but Cerus is the only company with both CE mark and FDA approval for pathogen reduction of platelets and plasma.
• The ReCePI study results are comparable to other studies demonstrating the safety and efficacy of pathogen-reduced blood products, but the specific non-inferiority endpoint in cardiac surgery patients is a unique aspect of this trial.

Stakeholder Impact

• Shareholders may react positively to the new BARDA contract but negatively to the CE Mark rejection.
• Employees may be encouraged by the continued funding and progress in the U.S. program.
• Customers (blood centers and hospitals) will be interested in the progress of the INTERCEPT RBC system.
• Suppliers may see increased demand for components of the INTERCEPT RBC system.
• Creditors will be reassured by the new funding and the company's continued development efforts.

Next Steps

• Cerus will continue to enroll patients in the RedeS clinical trial.
• The company will submit a modular PMA application to the FDA upon completion of the RedeS trial.
• Cerus will assess strategies for a potential new regulatory submission in Europe.
• The company will present study data at the Annual AABB meeting.

Key Dates

Keywords

INTERCEPT, red blood cell, BARDA, FDA, CE Mark, PMA, clinical trial, pathogen reduction, regulatory submission, blood transfusion